Ahmad shah Farhat; Ashraf Mohammadzadeh; Ezzat Khodashenas; saeed reza lotfi; negar yeganeh khorasani
Abstract
Introduction: Neonatal jaundice is a very important problem that occurs in 80% of premature infants. Treatments for jaundice include phototherapy and blood transfusions. But phototherapy is expensive and covering the eyes disrupts the relationship between mother and child. Also, in bilirubin above 20, ...
Read More
Introduction: Neonatal jaundice is a very important problem that occurs in 80% of premature infants. Treatments for jaundice include phototherapy and blood transfusions. But phototherapy is expensive and covering the eyes disrupts the relationship between mother and child. Also, in bilirubin above 20, the power of reducing bilirubin due to phototherapy is not so highMethods: Samples will be selected by the probabilistic method. The infants were admitted to the study at the NICU of Imam Reza and Samen Al-A'meh Hospitals in Mashhad. Random allocation is given in one of the two phenobarbital or case and the placebo groups. Routine laboratory tests for jaundice are performed for all infants. Then phototherapy and medicine are prescribed. Bilirubin levels are checked every 6, 12, 24, and 48 hours after medication and until discharge. After collecting information, the data is analyzed with SPSS software version 16.Results: According to these results, there were no significant differences between sex, gestational age, infant weight and age in two groups. The mean and standard deviation of bilirubin levels before the intervention and after intervention were not significantly different between the two groups after 6 , 12, 24,48 hours, and discharge time. Conclusion: Phototherapy with 20 mg/kg phenobarbital was prescribed for the study group and only phototherapy was performed for the control group. In neonates with jaundice, phototherapy with phenobarbital 20 mg single dose did not reduce bilirubin levels and length of hospital stay.
Somayyeh Hashemian; Ashraf Mohammad zadeh; Alireza Ataee nakhaei
Abstract
Hyperbilirubinemia is a common disease and unconjugated hyperbilirubinemia has been seen mainly in neonates. Severe form of unconjugated hyperbilirubinemia may cause kernicterus and even death. Conventional treatment for severe unconjugated hyperbilirubinemia consists of phototherapy and exchange transfusion ...
Read More
Hyperbilirubinemia is a common disease and unconjugated hyperbilirubinemia has been seen mainly in neonates. Severe form of unconjugated hyperbilirubinemia may cause kernicterus and even death. Conventional treatment for severe unconjugated hyperbilirubinemia consists of phototherapy and exchange transfusion that have several known disadvantages; specially exchange transfusion is associated with a significant morbidity and even mortality. These harmful effects indicate the need to develop alternative pharmacological treatment strategies for unconjugated hyperbilirubinemia. One of these pharmacological agents is zinc salts. Zinc has been shown to lower the bilirubin levels by inhibition of the enterohepatic cycling of unconjugated bilirubin. Oral zinc has been shown to reduce serum unconjugated bilirubin in animals, adolescents and low birth weight neonates. However, studies in healthy term neonates given oral zinc showed no reduction in hyperbilirubinemia based on daily measurement. In order to improve the accuracy, hyperbilirubinemia may be determined based on measurements every hour. More studies are needed to know the effect of zinc in neonatal jaundice.